Skip to main content

Biologics

Treatment of MIS-C COVID in Kids

Jun 21, 2021

The NEJM has published results of a real-world efficacty trial showing that COVID infected children with the multisystem inflammatory syndrome in children (MIS-C) respond better to initial IVIG plus glucocorticoids (than IVIG alone) which was associated with less subsequent cardiovascular

Read Article
Is Rituximab and Belimumab the Combination to Beat Lupus? Dr. Eric Dein ( @ericdeinmd ) shares learnings from #EULAR2021. https://t.co/r4aNG7KR5h https://t.co/2kedsCL904
Dr. John Cush @RheumNow( View Tweet )
Jun 21, 2021

Do B-cell targeted therapies still have a place for the treatment of Sjogren’s?

B-cells play a major role in the pathogenesis of primary Sjogren’s syndrome (pSS) through antibody-dependent and antibody-independent functions, as well as evident by progression to B-cell malignancies/lymphoma. Hence, targeting B-cell is attractive. Despite efficacy of B-cell depleting therapy

Read Article

Reader beware! Interpretation of effectiveness & safety of JAKi vs bDMARDs in real world data

Multiple studies compared effectiveness, retention and/or safety of biological DMARDs (bDMARDs) and JAK inhibitors (JAKi) at EULAR 2021. But be careful of what you read because depending on age, gender, comorbidities, line of therapy and access to treatment, you may find highly variable

Read Article

EULAR 2021 – Day 4 Report

Jun 17, 2021

It's been nearly two weeks since EULAR 21 ended. There were several presentations on the last day; notably, the late breaking abstracts and others. Here are a few of my favorites from Day 4, the final day of the meeting.

Read Article

Problems at the FDA

Jun 16, 2021

"While the Food and Drug Administration decision on new drugs usually follows the recommendations of the advisory committee..."; this oft used proviso is used to either indicate a pending FDA decision or an FDA decision that is contrary to the recommendation of the advisory committee convened

Read Article

RheumNow Podcast - Best of EULAR 2021

Jun 11, 2021

Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.

Read Article

Q-DAPSA for Measuring Disease Activity in PsA

Jun 10, 2021

Given its multiple domains, there remains much discussion over the best disease activity scoring method in PsA. The proverbial "holy grail" would be a measure that is quick, intuitive, domain comprehensive and validated.

Read Article

Lessons learned in SLE

An analysis of SLE samples from SLE 1760 patients with active disease from RCTs illustrated several known and some new targets for SLE treatment (POS0351). Markers of pathways

Read Article

Combination vs. Sequential Therapy for the Treatment of Lupus Nephritis

Jun 08, 2021

Combination disease modifying antirheumatic drug (DMARD) therapy may not be only for rheumatoid arthritis; combining disease modifying agents may be the path to better renal response. 

Read Article
#EULAR2021 - Day 3 Report https://t.co/X7zxsKW8eL https://t.co/OKu5Mgodlo
Dr. John Cush @RheumNow( View Tweet )
Jun 08, 2021

EULAR 2021 - Day 3 Report

Jun 07, 2021

Here are a few notable presentations from this past Friday, Day 3 of the EULAR 2021 virtual meeting.

Read Article

How do we personalize psoriatic arthritis treatment?

Jun 07, 2021

It seems like every conference we are presented with data on the newest biologic for treatment of psoriatic arthritis, but the question is, do we need it?



Oral presentation (6937) discussed that issue and addressed our need for a more personalized approach to the treatment of PsA. 

Read Article

Israel provides COVID vaccine answers for rheumatic disease patients

Jun 07, 2021

The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress, data presented from Israel, one of the first countries to vaccinate on a broad scale, has

Read Article

RA after 70: Too Old for bioDMARDs?

In RA, the two most common peaks of incidence are thirties and fifties; however a significant percentage of patients above the age of 70 present with active RA -of early or later onset- and require adapted treatment.



Importantly, treating people living with RMDs above the age of 70 -

Read Article
OP0140 at #EULAR2021: ➡️Obs, prospect Nordic study characterized axSpA pts w/ high BASDAI + ASDAS & multiple bDMARD use (indicating difficult to tx dz) ➡️1 in 10 received at least 3 bDMARDs *⃣Multiple switchers were more often F, had higher b/l dz activity, & psoriasis @Rheumnow https://t.co/syq0szVWKe
Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )
Jun 06, 2021
Baseline Vitamin D 😎☀️correlated with biologic response in RA pts. ⭐️EULAR good response: 19.6% Vit D >20 vs 4.2%⬇️Vit D ⭐️Remission: 14.4% ⬆️Vit D vs 3.2% ⬇️Vit D Abs#POS0100 #EULAR2021 @RheumNow

Robert B Chao, MD @doctorRBC( View Tweet )

Jun 06, 2021
No clear winner here. The majority would use #IL23 inhibitors as either 2nd or 3rd line bDMARDs and for #psoriaticarthritis with severe #psoriasis. Thank you for participating in the polls #EULAR2021 @RheumNow https://t.co/b8wzaRVTqw

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )

Jun 06, 2021
Rituximab in PMR. Intriguing proof of concept (SB?) RCT (1:1, total n=47 (recent dx 38/relapsing 9)) 17w rapid PNL taper ritux 1g x1 21w: steroid-free remission: 48% v 21% PNL ≤5mg/d: 100% v 54% effect mainly from recent dx pts We do need options! POS0343 #EULAR2021 @RheumNow https://t.co/g6xJekY92O
David Liew @drdavidliew( View Tweet )
Jun 06, 2021
HUR-BIO real life data, PsA pts started bDMARDs w/in 18 mo of dx vs almost 3x later in RA pts (tended to remain on csDMARDs.) This distinction may be explained by synthetic DMARDs on activity differences between the RA & PsA. Abstract #POS0633 #EULAR2021 https://t.co/VkkF28jm2f https://t.co/IkfGdZYNY3
Dr. Rachel Tate @uptoTate( View Tweet )
Jun 05, 2021
Poster #POS0633 detailed HUR-BIO PsA pts started bDMARDs w/in 18 months of dx vs, on ave, 3x longer to start bDMARDs in RA pts in real life data. What do you drugs do you start in your PsA pts after dx? Feel free to detail me below! #EULAR2021 @RheumNow

Dr. Rachel Tate @uptoTate( View Tweet )

Jun 05, 2021
Dr Marsman presents positive RCT of Rituximab in PMR. GC-free remission 48% vs 21% (p=0.049) GC<=5mg 100% vs 47% (p=0.005) @RheumNow #EULAR2021 Abstr#POS0343 https://t.co/tjkKTS6DMN
Richard Conway @RichardPAConway( View Tweet )
Jun 05, 2021
#POS0022 prosp study of CTZ pregnancies: 1392 preg w/1425 outcomes @UCBUSA database 88.4% live births, 10.5% preg loss, 0.8% still birth 2.4% congen malform (w/2.1% major) Preg loss⬅️Crohn's, NSAIDS, MTX Preterm labor⬅️GCs, maternal infx ⬇️birth wt⬅️RA & GCs @rheumnow #EULAR2021 https://t.co/qnNcDIz8Ge
Jun 05, 2021
Real-world data from PsABio: 🚺generally start biologics in a worse PsA state than🚹. Although treatment improvements were similar between sexes, 🚺remained in worse health at 1 yr, and stopped/switched bDMARD earlier. Abstract #OP0232 #EULAR2021 @RheumNow https://t.co/oIGu0HzisQ https://t.co/uLnYOq8ypx
Dr. Rachel Tate @uptoTate( View Tweet )
Jun 05, 2021
#EULAR2021 and EULAR IQ Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021. https://t.co/BkHjhOUqNU https://t.co/4JS1yGiJHg
Dr. John Cush @RheumNow( View Tweet )
Jun 05, 2021
×